Drug intelligence / Profile preview

RH119

Development stage: Unknown
Lead developer: Wuhan Ruiji Biotechnology
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

RH119 is a lyophilized mRNA vaccine developed by Wuhan Ruiji Biotechnology Co., Ltd. and Wuhan Jinyintan Hospital for the prevention of tuberculosis. It is designed to deliver messenger RNA (mRNA) encoding specific antigens of Mycobacterium tuberculosis, prompting the host's cells to produce these antigens and stimulate a protective immune response against the disease.

Beyond the preview

Go deeper on RH119.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RH119.

Explore the full profile